UltraGreen.ai is preparing for the uncertainty of the American market. The company's growth has been estimated at an 43.9% increase in Q3 of the current year, with a 47% increase in US market revenues. These figures have been highlighted in its annual report published on October 29th.

The rest of the global market has seen a 32% increase on the total of $9.4 million in 2025. For the past nine months, sales have increased by 35% compared to the previous period, reaching $131.8 million. Zydus and Provepharm have received licenses to produce and sell ICG in America, which has led to price pressure and changes in customer purchase trends.

UltraGreen.ai announced that it expects a financial war in 2026, with a recompense of 30% of net income and plans to acquire investments worth $30 million. The company stated that it is preparing to face market uncertainty through collaboration with distributors and commercial partners, improving customer relations and monitoring competitor buying trends.

The company has also released a new generic ICG offer through its distributors in America, providing a competitive alternative to its brand options. Additionally, the company is engaged in efficiency operations and cost development to support profitability in the changing market environment.

The board approved a capitalization plan prioritizing the company's commitment, followed by annual payments of at least 30% of net income, distributed over two annual periods, considering the results of the current year. This news has generated great interest among financial analysts, as it shows how the medical company is preparing to face the uncertainty of the American market and the potential war that could be launched in 2026.